Research programme: RDP 58 analogues - Sanofi Genzyme/Synt:em

Drug Profile

Research programme: RDP 58 analogues - Sanofi Genzyme/Synt:em

Alternative Names: Research programme: RDP58 analogues - Sanofi Genzyme/Synt:em

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation; Synt:em
  • Class Small molecules
  • Mechanism of Action Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 04 May 2006 No development reported - Preclinical for Inflammation in Europe (unspecified route)
  • 30 Mar 2004 SangStat's operations have been absorbed into Genzyme Corporation's Cambridge site
  • 18 Sep 2003 SangStat has been acquired by Genzyme Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top